- Home
- BTM vs ALXO Comparison
BTM vs ALXO Comparison
Compare BTM & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTM
- ALXO
- Stock Information
- Founded
- BTM 2016
- ALXO 2015
- Country
- BTM United States
- ALXO United States
- Employees
- BTM N/A
- ALXO N/A
- Industry
- BTM Finance: Consumer Services
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- BTM Finance
- ALXO Health Care
- Exchange
- BTM Nasdaq
- ALXO Nasdaq
- Market Cap
- BTM 23.1M
- ALXO 24.0M
- IPO Year
- BTM N/A
- ALXO 2020
- Fundamental
- Price
- BTM $4.67
- ALXO $0.58
- Analyst Decision
- BTM Strong Buy
- ALXO Strong Buy
- Analyst Count
- BTM 2
- ALXO 6
- Target Price
- BTM $4.75
- ALXO $3.30
- AVG Volume (30 Days)
- BTM 2.5M
- ALXO 445.9K
- Earning Date
- BTM 05-15-2025
- ALXO 05-08-2025
- Dividend Yield
- BTM N/A
- ALXO N/A
- EPS Growth
- BTM N/A
- ALXO N/A
- EPS
- BTM N/A
- ALXO N/A
- Revenue
- BTM $599,390,000.00
- ALXO N/A
- Revenue This Year
- BTM $7.48
- ALXO N/A
- Revenue Next Year
- BTM $0.05
- ALXO N/A
- P/E Ratio
- BTM N/A
- ALXO N/A
- Revenue Growth
- BTM N/A
- ALXO N/A
- 52 Week Low
- BTM $0.93
- ALXO $0.41
- 52 Week High
- BTM $4.80
- ALXO $9.40
- Technical
- Relative Strength Index (RSI)
- BTM 76.62
- ALXO 60.39
- Support Level
- BTM $4.01
- ALXO $0.52
- Resistance Level
- BTM $4.80
- ALXO $0.59
- Average True Range (ATR)
- BTM 0.49
- ALXO 0.04
- MACD
- BTM 0.10
- ALXO 0.02
- Stochastic Oscillator
- BTM 94.06
- ALXO 94.10
About BTM Bitcoin Depot Inc.
Bitcoin Depot Inc owns and operates the largest network of BTMs across North America where customers can buy and sell Bitcoin. Bitcoin Depot helps power the digital economy for users of cash. It has locations across the U.S. and Canada at, among others, the following types of retailers: Convenience Stores and Gas Station Chains, Pharmacies and Grocers and Mall Operators.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.